TY - JOUR

T1 - Инновационные подходы к терапии тревожных и стресс-ассоциированных расстройств (резолюция Совета экспертов)

AU - Волель, Беатриса Альбертовна

AU - Кинкулькина, Марина Аркадьевна

AU - Абриталин, Евгений Юрьевич

AU - Охапкин, Роман Витальевич

AU - Житкова, Юлия Владимировна

AU - Зайцев, Олег Семенович

AU - Караваева, Татьяна Артуровна

AU - Костюк, Георгий Петрович

AU - Медведев, Владимир Эрнстович

AU - Парфенов, Владимир Анатольевич

AU - Самушия, Марина Антиповна

AU - Сорокин, Михаил Юрьевич

AU - Чумаков, Егор Максимович

AU - Мосолов, Сергей Николаевич

PY - 2026/8/18

Y1 - 2026/8/18

N2 - Anxiety and stress-related disorders are characterized by high prevalence, comorbidity and resistance to existing treatments in a significant proportion of patients. Treatment for anxiety spectrum disorders includes an educational program, psychotherapy and the use of medication. The most effective forms of psychotherapy are cognitive behavioural therapy and various relaxation techniques; in recent years, psychological methods have often been used not only in face-to-face sessions but also online. First-line treatments for anxiety spectrum disorders include selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). In some cases, patients with anxiety spectrum disorders do not respond to SSRIs and SNRIs, and many patients discontinue their medication due to adverse effects; therefore, the search for new drugs remains a priority. This article summarises the findings of the Expert Council meeting (April 2026) dedicated to maritupirdine (Aviandr®), a multi-target antagonist of serotonin, α2-adrenergic and H1-histamine receptors. Based on preclinical and clinical data, including studies on generalized anxiety disorder and post-COVID-19 adjustment disorder, the drug's anxiolytic, antidepressant and pro-cognitive effects, favourable safety profile and absence of withdrawal syndrome have been confirmed. A pro-cognitive effect of the drug has been observed, consistent with data on the blockade of 5-HT6 and 5-HT7 receptors. Experts conclude that the restrictions on the use of maritupirdine in patients with organic brain disorders and epilepsy are not sufficiently justified. Further research into maritupirdine in organic mental disorders, including cognitive impairment and dementia, is required. The use of maritupirdine is appropriate for adjustment disorders of various aetiologies. Maritupirdine's favourable tolerability and safety profile is a significant advantage in the treatment of patients with anxiety disorders and those with stress-related disorders.

AB - Anxiety and stress-related disorders are characterized by high prevalence, comorbidity and resistance to existing treatments in a significant proportion of patients. Treatment for anxiety spectrum disorders includes an educational program, psychotherapy and the use of medication. The most effective forms of psychotherapy are cognitive behavioural therapy and various relaxation techniques; in recent years, psychological methods have often been used not only in face-to-face sessions but also online. First-line treatments for anxiety spectrum disorders include selective serotonin reuptake inhibitors (SSRIs) and serotonin-norepinephrine reuptake inhibitors (SNRIs). In some cases, patients with anxiety spectrum disorders do not respond to SSRIs and SNRIs, and many patients discontinue their medication due to adverse effects; therefore, the search for new drugs remains a priority. This article summarises the findings of the Expert Council meeting (April 2026) dedicated to maritupirdine (Aviandr®), a multi-target antagonist of serotonin, α2-adrenergic and H1-histamine receptors. Based on preclinical and clinical data, including studies on generalized anxiety disorder and post-COVID-19 adjustment disorder, the drug's anxiolytic, antidepressant and pro-cognitive effects, favourable safety profile and absence of withdrawal syndrome have been confirmed. A pro-cognitive effect of the drug has been observed, consistent with data on the blockade of 5-HT6 and 5-HT7 receptors. Experts conclude that the restrictions on the use of maritupirdine in patients with organic brain disorders and epilepsy are not sufficiently justified. Further research into maritupirdine in organic mental disorders, including cognitive impairment and dementia, is required. The use of maritupirdine is appropriate for adjustment disorders of various aetiologies. Maritupirdine's favourable tolerability and safety profile is a significant advantage in the treatment of patients with anxiety disorders and those with stress-related disorders.

KW - 5-HT₆

KW - 5-HT₇

KW - Aviandr®

KW - adjustment disorder

KW - anxiety disorders

KW - cognitive impairment

KW - generalized anxiety disorder

KW - maritupirdine

KW - multi-target therapy

KW - pro-cognitive effect

KW - serotonin receptor antagonists

UR - https://www.mendeley.com/catalogue/96e59ac5-e6f6-33f9-93c9-bccd13408d5e/

U2 - 10.14412/2074-2711-2026-4-128-135

DO - 10.14412/2074-2711-2026-4-128-135

M3 - статья

VL - 18

SP - 128

EP - 135

JO - Неврология, нейропсихиатрия, психосоматика

JF - Неврология, нейропсихиатрия, психосоматика

SN - 2074-2711

IS - 4

ER -